Chapter/Section Purchase

1 Study Coverage
1.1 Personalized Medicine and Epigenomics Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million) Introduction
1.2 Global Personalized Medicine and Epigenomics Outlook 2017 VS 2022 VS 2028
1.2.1 Global Personalized Medicine and Epigenomics Market Size for the Year 2017-2028
1.2.2 Global Personalized Medicine and Epigenomics Market Size for the Year 2017-2028
1.3 Personalized Medicine and Epigenomics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Personalized Medicine and Epigenomics in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Personalized Medicine and Epigenomics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Personalized Medicine and Epigenomics Market Dynamics
1.4.1 Personalized Medicine and Epigenomics Industry Trends
1.4.2 Personalized Medicine and Epigenomics Market Drivers
1.4.3 Personalized Medicine and Epigenomics Market Challenges
1.4.4 Personalized Medicine and Epigenomics Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Personalized Medicine and Epigenomics by Type
2.1 Personalized Medicine and Epigenomics Market Segment by Type
2.1.1 Reagents
2.1.2 Kits
2.1.3 Instruments
2.1.4 Enzymes
2.1.5 Services
2.2 Global Personalized Medicine and Epigenomics Market Size by Type (2017, 2022 & 2028)
2.3 Global Personalized Medicine and Epigenomics Market Size by Type (2017-2028)
2.4 United States Personalized Medicine and Epigenomics Market Size by Type (2017, 2022 & 2028)
2.5 United States Personalized Medicine and Epigenomics Market Size by Type (2017-2028)
3 Personalized Medicine and Epigenomics by Application
3.1 Personalized Medicine and Epigenomics Market Segment by Application
3.1.1 Oncology
3.1.2 Non-Oncology
3.1.3 Cancer Drug Technology
3.2 Global Personalized Medicine and Epigenomics Market Size by Application (2017, 2022 & 2028)
3.3 Global Personalized Medicine and Epigenomics Market Size by Application (2017-2028)
3.4 United States Personalized Medicine and Epigenomics Market Size by Application (2017, 2022 & 2028)
3.5 United States Personalized Medicine and Epigenomics Market Size by Application (2017-2028)
4 Global Personalized Medicine and Epigenomics Competitor Landscape by Company
4.1 Global Personalized Medicine and Epigenomics Market Size by Company
4.1.1 Top Global Personalized Medicine and Epigenomics Companies Ranked by Revenue (2021)
4.1.2 Global Personalized Medicine and Epigenomics Revenue by Player (2017-2022)
4.2 Global Personalized Medicine and Epigenomics Concentration Ratio (CR)
4.2.1 Personalized Medicine and Epigenomics Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Personalized Medicine and Epigenomics in 2021
4.2.3 Global Personalized Medicine and Epigenomics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Personalized Medicine and Epigenomics Headquarters, Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million) Type
4.3.1 Global Personalized Medicine and Epigenomics Headquarters and Area Served
4.3.2 Global Personalized Medicine and Epigenomics Companies Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Personalized Medicine and Epigenomics Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Personalized Medicine and Epigenomics Market Size by Company
4.5.1 Top Personalized Medicine and Epigenomics Players in United States, Ranked by Revenue (2021)
4.5.2 United States Personalized Medicine and Epigenomics Revenue by Players (2020, 2021 & 2022)
5 Global Personalized Medicine and Epigenomics Market Size by Region
5.1 Global Personalized Medicine and Epigenomics Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Personalized Medicine and Epigenomics Market Size by Region (2017-2028)
5.2.1 Global Personalized Medicine and Epigenomics Market Size by Region: 2017-2022
5.2.2 Global Personalized Medicine and Epigenomics Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Personalized Medicine and Epigenomics Market Size YoY Growth 2017-2028
6.1.2 North America Personalized Medicine and Epigenomics Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Personalized Medicine and Epigenomics Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Personalized Medicine and Epigenomics Market Size YoY Growth 2017-2028
6.3.2 Europe Personalized Medicine and Epigenomics Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Personalized Medicine and Epigenomics Market Size YoY Growth 2017-2028
6.4.2 Latin America Personalized Medicine and Epigenomics Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Personalized Medicine and Epigenomics Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Personalized Medicine and Epigenomics Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Abbott Laboratories
7.1.1 Abbott Laboratories Company Details
7.1.2 Abbott Laboratories Business Overview
7.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Introduction
7.1.4 Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.1.5 Abbott Laboratories Recent Development
7.2 Affymetrix
7.2.1 Affymetrix Company Details
7.2.2 Affymetrix Business Overview
7.2.3 Affymetrix Personalized Medicine and Epigenomics Introduction
7.2.4 Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.2.5 Affymetrix Recent Development
7.3 Agilent Technologies
7.3.1 Agilent Technologies Company Details
7.3.2 Agilent Technologies Business Overview
7.3.3 Agilent Technologies Personalized Medicine and Epigenomics Introduction
7.3.4 Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.3.5 Agilent Technologies Recent Development
7.4 Astellas Pharmaceuticals
7.4.1 Astellas Pharmaceuticals Company Details
7.4.2 Astellas Pharmaceuticals Business Overview
7.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Introduction
7.4.4 Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.4.5 Astellas Pharmaceuticals Recent Development
7.5 BAYER AG
7.5.1 BAYER AG Company Details
7.5.2 BAYER AG Business Overview
7.5.3 BAYER AG Personalized Medicine and Epigenomics Introduction
7.5.4 BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.5.5 BAYER AG Recent Development
7.6 Bio Vision
7.6.1 Bio Vision Company Details
7.6.2 Bio Vision Business Overview
7.6.3 Bio Vision Personalized Medicine and Epigenomics Introduction
7.6.4 Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.6.5 Bio Vision Recent Development
7.7 Celgene Corp.
7.7.1 Celgene Corp. Company Details
7.7.2 Celgene Corp. Business Overview
7.7.3 Celgene Corp. Personalized Medicine and Epigenomics Introduction
7.7.4 Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.7.5 Celgene Corp. Recent Development
7.8 Emd Millipore
7.8.1 Emd Millipore Company Details
7.8.2 Emd Millipore Business Overview
7.8.3 Emd Millipore Personalized Medicine and Epigenomics Introduction
7.8.4 Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.8.5 Emd Millipore Recent Development
7.9 Epigenomics AG
7.9.1 Epigenomics AG Company Details
7.9.2 Epigenomics AG Business Overview
7.9.3 Epigenomics AG Personalized Medicine and Epigenomics Introduction
7.9.4 Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.9.5 Epigenomics AG Recent Development
7.10 Epigentex
7.10.1 Epigentex Company Details
7.10.2 Epigentex Business Overview
7.10.3 Epigentex Personalized Medicine and Epigenomics Introduction
7.10.4 Epigentex Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.10.5 Epigentex Recent Development
7.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
7.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
7.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
7.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Introduction
7.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
7.12 Gilead Sciences
7.12.1 Gilead Sciences Company Details
7.12.2 Gilead Sciences Business Overview
7.12.3 Gilead Sciences Personalized Medicine and Epigenomics Introduction
7.12.4 Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.12.5 Gilead Sciences Recent Development
7.13 Glaxosmithkline
7.13.1 Glaxosmithkline Company Details
7.13.2 Glaxosmithkline Business Overview
7.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Introduction
7.13.4 Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.13.5 Glaxosmithkline Recent Development
7.14 Illumina Inc.
7.14.1 Illumina Inc. Company Details
7.14.2 Illumina Inc. Business Overview
7.14.3 Illumina Inc. Personalized Medicine and Epigenomics Introduction
7.14.4 Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.14.5 Illumina Inc. Recent Development
7.15 Johnson & Johnson
7.15.1 Johnson & Johnson Company Details
7.15.2 Johnson & Johnson Business Overview
7.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Introduction
7.15.4 Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.15.5 Johnson & Johnson Recent Development
7.16 Karus Therapeutics Limited
7.16.1 Karus Therapeutics Limited Company Details
7.16.2 Karus Therapeutics Limited Business Overview
7.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Introduction
7.16.4 Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.16.5 Karus Therapeutics Limited Recent Development
7.17 Laboratory Corp. Of America Holdings
7.17.1 Laboratory Corp. Of America Holdings Company Details
7.17.2 Laboratory Corp. Of America Holdings Business Overview
7.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Introduction
7.17.4 Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.17.5 Laboratory Corp. Of America Holdings Recent Development
7.18 LES Laboratoires Servier
7.18.1 LES Laboratoires Servier Company Details
7.18.2 LES Laboratoires Servier Business Overview
7.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Introduction
7.18.4 LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.18.5 LES Laboratoires Servier Recent Development
7.19 Merck
7.19.1 Merck Company Details
7.19.2 Merck Business Overview
7.19.3 Merck Personalized Medicine and Epigenomics Introduction
7.19.4 Merck Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.19.5 Merck Recent Development
7.20 Naturewise Biotech & Medicals Corp.
7.20.1 Naturewise Biotech & Medicals Corp. Company Details
7.20.2 Naturewise Biotech & Medicals Corp. Business Overview
7.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Introduction
7.20.4 Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.20.5 Naturewise Biotech & Medicals Corp. Recent Development
7.21 Novartis Pharma AG
7.21.1 Novartis Pharma AG Company Details
7.21.2 Novartis Pharma AG Business Overview
7.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Introduction
7.21.4 Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.21.5 Novartis Pharma AG Recent Development
7.22 Oncolys Biopharma Inc.
7.22.1 Oncolys Biopharma Inc. Company Details
7.22.2 Oncolys Biopharma Inc. Business Overview
7.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Introduction
7.22.4 Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.22.5 Oncolys Biopharma Inc. Recent Development
7.23 Orchid Chemicals & Pharmaceuticals Limited
7.23.1 Orchid Chemicals & Pharmaceuticals Limited Company Details
7.23.2 Orchid Chemicals & Pharmaceuticals Limited Business Overview
7.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
7.23.4 Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.23.5 Orchid Chemicals & Pharmaceuticals Limited Recent Development
7.24 Progen Pharmaceuticals Limited
7.24.1 Progen Pharmaceuticals Limited Company Details
7.24.2 Progen Pharmaceuticals Limited Business Overview
7.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
7.24.4 Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.24.5 Progen Pharmaceuticals Limited Recent Development
7.25 Quest Diagnostics
7.25.1 Quest Diagnostics Company Details
7.25.2 Quest Diagnostics Business Overview
7.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Introduction
7.25.4 Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.25.5 Quest Diagnostics Recent Development
7.26 Roche Holding AG
7.26.1 Roche Holding AG Company Details
7.26.2 Roche Holding AG Business Overview
7.26.3 Roche Holding AG Personalized Medicine and Epigenomics Introduction
7.26.4 Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.26.5 Roche Holding AG Recent Development
7.27 Rubicon Genomics
7.27.1 Rubicon Genomics Company Details
7.27.2 Rubicon Genomics Business Overview
7.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Introduction
7.27.4 Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.27.5 Rubicon Genomics Recent Development
7.28 Takeda Pharmaceutical Company Limited
7.28.1 Takeda Pharmaceutical Company Limited Company Details
7.28.2 Takeda Pharmaceutical Company Limited Business Overview
7.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Introduction
7.28.4 Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
7.28.5 Takeda Pharmaceutical Company Limited Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer